The decision counters a proposal by the Biden Administration to reimburse beneficiaries for the weight-loss medications.

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

Emergency room visits attributed to popular weight loss drugs such as Ozempic and Wegovy remain quite rare overall, but do ...

A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 ...

The most popular weight-loss drugs are made by Novo Nordisk, which sells its medicine as Wegovy for obesity and as Ozempic for diabetes, and by Eli Lilly, which sells its product as Zepbound for ...

The Trump administration has decided not to go forward with a proposal for Medicare and Medicaid to cover high-demand obesity ...

The Trump administration reversed a Biden-era proposal for Medicare coverage of anti-obesity treatments. But on Monday, HHS ...

The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on ...

The Trump administration has chosen not to finalize a rule proposed by the Biden administration that would have allowed ...

Under Friday’s final ruling anti-obesity medications for weight-loss will remain ineligible for Medicare coverage.

The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded ...